Artal Group’s Halozyme HALO Stock Holding History

Artal Group’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-150,000	Closed	-$3.04M	–	123
2017 Q4	$3.04M	Buy	+150,000	New	+$2.76M	0.05%	86

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group's HALO Position: Q1 2018 in Review

Artal Group sold out of Halozyme (HALO) in Q1 2018, closing a stake of 150,000 shares — an estimated $3.04M sold.

Artal Group first reported a position in HALO in Q4 2017 and held it in 1 quarter. The position peaked at $3.04M in Q4 2017. 209 funds tracked by Wall St. Rank hold HALO as of Q1 2018.

Artal Group reported no remaining Halozyme position as of Q1 2018 after selling out during the quarter.
Artal Group sold 150,000 Halozyme shares in Q1 2018, an estimated $3.04M.
Artal Group first reported a position in Halozyme in Q4 2017 and held it in 1 quarter.
Artal Group's Halozyme position peaked at $3.04M in Q4 2017.
209 funds tracked by Wall St. Rank held Halozyme as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.